PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/207749

Please be advised that this information was generated on 2021-01-03 and may be subject to change.
The role of small diffusion-weighted imaging lesions in cerebral small vessel disease

Kim Wiegertjes, MSc,* Annemieke ter Telgte, MSc,* Pedro B. Oliveira, MD, Esther M.C. van Leijsen, PhD, Mayra I. Bergkamp, MSc, Ingeborg W.M. van Uden, MD, PhD, Mohsen Ghafoorian, PhD, Helena M. van der Holst, MD, PhD, David G. Norris, PhD, Bram Platel, PhD, Catharina J.M. Klijn, MD, PhD, Anil M. Tuladhar, MD, PhD, and Frank-Erik de Leeuw, MD, PhD

Neurology® 2019;93:e1627-e1634. doi:10.1212/WNL.0000000000008364

Abstract

Objective
To investigate the prevalence of asymptomatic diffusion-weighted imaging–positive (DWI+) lesions in individuals with cerebral small vessel disease (SVD) and identify their role in the origin of SVD markers on MRI.

Methods
We included 503 individuals with SVD from the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort (RUN DMC) study (mean age 65.6 years [SD 8.8], 56.5% male) with 1.5T MRI in 2006 and, if available, follow-up MRI in 2011 and 2015. We screened DWI scans (n = 1,152) for DWI+ lesions, assessed lesion evolution on follow-up fluid-attenuated inversion recovery, T1 and T2* images, and examined the association between DWI+ lesions and annual SVD progression (white matter hyperintensities [WMH], lacunes, microbleeds).

Results
We found 50 DWI+ lesions in 39 individuals on 1,152 DWI (3.4%). Individuals with DWI+ lesions were older (p = 0.025), more frequently had a history of hypertension (p = 0.021), and had a larger burden of preexisting SVD MRI markers (WMH, lacunes, microbleeds: all p < 0.001) compared to individuals without DWI+ lesions. Of the 23 DWI+ lesions with available follow-up MRI, 14 (61%) evolved into a WMH, 8 (35%) resulted in a cavity, and 1 (4%) was no longer visible. Presence of DWI+ lesions was significantly associated with annual WMH volume increase and yearly incidence of lacunes and microbleeds (all p < 0.001).

Conclusion
Over 3% of individuals with SVD have DWI+ lesions. Although DWI+ lesions play a role in the progression of SVD, they may not fully explain progression of SVD markers on MRI, suggesting that other factors than acute ischemia are at play.

*These authors contributed equally to this work.

From the Department of Neurology (K.W., A.t.T., P.B.O., E.M.C.v.L., M.I.B., I.W.M.v.U., H.M.v.d.H., C.J.M.K., A.M.T., F.-E.d.L.) and Center for Cognitive Neuroimaging (D.G.N.), Donders Institute for Brain, Cognition and Behavior, and Diagnostic Image Analysis Group, Department of Radiology and Nuclear Medicine (M.G., B.P.), Radboud University Medical Center; and Institute for Computing and Information Sciences (M.G.), Radboud University, Nijmegen, the Netherlands.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Cerebral small vessel disease (SVD) is the most important vascular contributor to dementia. MRI markers of SVD include white matter hyperintensities (WMH), lacunes, and microbleeds. It is generally assumed that chronic hypoperfusion plays a role in the etiology of SVD, although this has never been proven in longitudinal studies.

Previous cross-sectional evidence has suggested that diffusion-weighted imaging–positive (DWI+) lesions representing acute ischemia are associated with SVD. DWI+ lesions may be clinically silent, with a prevalence ranging from <1% in the general population to 8% in patients with hypertensive SVD and up to 23% in individuals with cerebral amyloid angiopathy (CAA). However, the role of DWI+ lesions in SVD progression remains unclear.

Recent longitudinal studies have suggested that DWI+ lesions might evolve into a spectrum of SVD markers, including a WMH, lacune, or microbleed. However, these recent studies were small, had a short duration of follow-up, or did not investigate the whole SVD spectrum. Therefore, the contribution of DWI+ lesions to the progression of SVD markers during long-term follow-up remains unknown.

Our aims were (1) to investigate the prevalence of DWI+ lesions in individuals with SVD and (2) to identify their role in the origin of the spectrum of SVD MRI markers by capturing evolution of the DWI+ lesions during a 9-year follow-up and (3) by examining the relation between the occurrence of DWI+ lesions and progression of MRI markers of SVD within this time period.

**Methods**

**Study population**

We selected 503 participants with SVD aged between 50 and 85 years from the prospective Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort (RUN DMC) study. The clinical manifestation of SVD can present in acute (e.g., TIA or lacunar syndromes) and subacute form (e.g., cognitive and motor impairment). However, we based the selection of participants on MRI markers of SVD including WMH or lacunes, as clinical symptoms of SVD are often diverse with a subtle onset.

Participants were excluded if they had dementia, (psychiatric) disease interfering with testing or follow-up, SVD mimics, or MRI contraindications including known claustrophobia. We included all 503 participants with MRI at baseline, of which 361 participants underwent a first follow-up MRI examination (follow-up interval 5.4 years [range 4.6–6.2]) and 296 individuals underwent a second follow-up (follow-up interval 3.4 years [range 2.7–4.1]; figure 1).

**Standard protocol approvals, registrations, and patient consents**

The Medical Review Ethics Committee Region Arnhem–Nijmegen approved the study, and all participants gave written informed consent.

**Magnetic resonance imaging**

All images were collected on a 1.5T MRI system (2006: Siemens [Munich, Germany], Magnetom Sonata; 2011 and 2015: Siemens, Magnetom Avanto), using the same head coil. Acquisition details have been described previously. In short, the following whole-brain scans were included: 3D T1 magnetization-prepared rapid gradient echo imaging (voxel size 1.0 × 1.0 × 1.0 mm); fluid-attenuated inversion recovery (FLAIR) pulse sequences (2006: voxel size 0.5 × 0.5 × 5.0 mm, interslice gap 1.0 mm; 2011 and 2015: voxel size 0.5 × 0.5 × 2.5 mm, interslice gap 0.5 mm); diffusion-weighted sequence designed for diffusion-tensor imaging (voxel size 2.5 × 2.5 × 2.5 mm, 4 unweighted scans, 30 diffusion-weighted scans, b-value 900 s/mm²); and a transversal T2*-weighted gradient echo sequence (voxel size 1.3 × 1.0 × 5.0 mm, interslice gap 1.0 mm).

**Detection of DWI+ lesions and their time course**

Preprocessing of diffusion data have been described previously. This included correction for eddy current-induced distortions and participant motion using an in-house developed algorithm and echoplanar imaging distortion correction by means of normalization to the T1 image in the phase-encoding direction. We used the diffusion data to calculate mean diffusivity (MD) images and trace images based on the geometric mean of all diffusion-weighted images. DWI indicative of DWI+ lesions were selected by a blinded rater (P.B.O.). The intensity of MD maps at the corresponding location was noted (hypointense, isointense, or hyperintense) and interpreted as lesion age. Inter-rater agreement with an experienced and trained rater (K.W.) in a random sample of 5% (n = 58) showed excellent agreement (Cohen κ = 0.8, 95% confidence interval [CI] 0.5–1.0). Subsequently, identified DWI+ lesions were confirmed as

---

**Glossary**

CAA = cerebral amyloid angiopathy; CI = confidence interval; DTI = diffusion tensor imaging; DWI+ = diffusion-weighted imaging–positive; FLAIR = fluid-attenuated inversion recovery; ICV = intracranial volume; MD = mean diffusivity; MMSE = Mini-Mental State Examination; RUN DMC = Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort; STRIVE = Standards for Reporting Vascular Changes on Neuroimaging; SVD = small vessel disease; VIF = variance inflation factor; WMH = white matter hyperintensities.
definite lesions by 2 stroke neurologists (A.M.T. and F.-E.d.L.). Lesions were excluded if hyperintense on DWI scans at more than one time point as this implied most likely a T2 shine-through, hypointense on initial T2* scans suggesting microbleed-related susceptibility artifacts, or if any clinical symptoms were reported as we aimed to include clinically silent DWI+ lesions.

The appearance of the lesion on follow-up imaging was assessed by 2 experienced raters in consensus (K.W. and A.t.T.) on available FLAIR, T1, T2, and T2*-weighted sequences coregistered to the individual’s DWI scan at the time of the lesion. Prior to coregistration, all images were skull-stripped using the Brain Extraction Tool from the FMRIB Software Library.20 Using the FSL Linear Image Registration Tool (cost, mutual info), we coregistered brain-extracted T1 images to diffusion tensor imaging (DTI) space and subsequently used the computed coregistration measures to coregister FLAIR, T2, and T2* images to DTI space. All images were visually checked for coregistration errors.

Other neuroimaging markers
SVD markers were annotated according to the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) criteria.3 WMH volumes were segmented by a semiautomatic in-house developed tool,21 visually adjusted for errors by one trained rater (I.W.M.v.U.), and normalized to baseline intracranial volume (ICV) as calculated by SPM12 (filion.ucl.ac.uk/spm/software/spm12/). Number and location of lacunes and microbleeds were rated manually on FLAIR/T1-weighted and T2*-weighted images by 2 trained raters (I.W.M.v.U. and M.I.B.) blinded to clinical data. Interrater and intrarater reliabilities were excellent (weighted $\kappa \geq 0.85$ in a random sample of 10%).22 ICV was calculated by adding gray matter volume, white matter volume, and CSF volume.

Vascular risk factors
We assessed the presence of vascular risk factors through standardized structured questionnaires and physical examination, including smoking, hypertension, body mass index, diabetes, and hypercholesterolemia, as described previously.15
Statistical analysis

Statistical analyses were performed in R (version 3.2.2). We compared participants with or without DWI+ lesions regarding demographics, vascular risk factors, and SVD imaging markers. We used independent sample t tests for group comparisons of normally distributed data and the Wilcoxon rank sum test (Mann-Whitney U test) for non-normally distributed data (age, WMH volume, and scores on the Mini-Mental State Examination [MMSE]). We used the Fisher exact test for group comparisons of categorical data.

We investigated the relation between DWI+ lesions and annual SVD progression by linear regression analyses (model 1) using R function lm (Package stats version 3.2.4). We defined annual SVD progression as the increase in WMH volume, number of lacunes or microbleeds over the available follow-up period divided by the number of follow-up years. We used multivariable linear regression analysis to account for possible age-related effects (model 2). Subsequently, we assessed the relations between DWI+ lesions and SVD progression, adjusting for preexisting WMH volume, number of lacunes, and number of microbleeds at the time of the DWI+ lesion (model 3).

Finally, we calculated the variance inflation factor (VIF) to assess multicollinearity among predictors in model 3, as DWI+ lesions have been shown to evolve into WMH, lacunes, and microbleeds over time. The individual VIF values for preexisting SVD markers were all below 2.5 (WMH = 1.3, lacunes = 1.1, microbleeds = 1.2). We therefore concluded that multicollinearity was unlikely.

Two-tailed p values <0.05 were considered statistically significant. Data analysis was completed from January 2017 to June 2018.

Data availability

Data from the RUN DMC study including data supporting the findings of this study are available from the corresponding author on request.

Results

The 503 participants had a mean age of 65.6 years (SD 8.8) and 284 were male (56.5%). In total, 1,152 DWI scans were collected over the 3 different time points and assessed for DWI+ lesions. A total of 39 participants had one or more DWI+ lesion at any MRI time point (39/1,152; 3.4%; figure 1). We identified 50 DWI+ lesions, of which 38 were located in the white matter, 3 in the cortex, 4 in the deep gray matter, 2 in the cerebellum, and 3 overlapped both the white matter and cortex. The MD signal values at lesion locations were hypointense (n = 16) or isointense (n = 28) in most cases, suggesting that these lesions were caught in the acute phase. Six lesions were captured in the subacute phase indicated by a hyperintensity on MD scans, which can typically be detected within a few weeks after the event.

Differences between participants with and without DWI+ lesions

Baseline demographics, vascular risk factors, and SVD imaging markers in participants with and without DWI+ lesions are summarized in table 1. Participants with at least 1 DWI+ lesion at any MRI time point (n = 39) were older than participants without any DWI+ lesions (p = 0.025) but groups did not differ in sex, educational level, or MMSE score, although a negative trend was observed for a lower MMSE in individuals with a DWI+ lesion (p = 0.052). Moreover, individuals with a DWI+ lesion had a higher WMH volume and more frequently a lacune or microbleed (all p < 0.001) at baseline. The proportion of individuals with hypertension was higher in the group with a DWI+ lesion (p = 0.021), whereas other vascular risk factors did not differ significantly between groups.

Evolution of DWI+ lesions

Follow-up imaging for assessment of lesion evolution was available for 23 out of 50 DWI+ lesions. On first (if available) second follow-up MRI, 22 (out of the 23 DWI+ lesions) converted to MRI markers of SVD at the exact location of the former DWI+ lesion (table 2). One lesion was no longer visible on the second MRI 5 years later. These 22 markers of SVD on follow-up appeared as a WMH in 14, whereas 8 lesions were visible as a cavity or a lacune. Of the 8 cavity lesions, 2 were smaller than the standard size for a lacune of presumed vascular origin (3–15 mm) as described in the STRIVE criteria, whereas the remaining 6 lesions did meet these criteria.3 One DWI+ lesion that evolved into a cavity smaller than a lacune was located next to a hypointensity on T2*-weighted MRI, which remained visible on follow-up MRI, suggesting mixed (hemorrhagic and ischemic) pathology (figure 2C).

DWI+ lesions and SVD progression

Participants with DWI+ lesions at either the first or second MRI (n = 16) had a higher annual WMH progression (β = 0.173, 95% CI 0.072–0.274, p < 0.001), a higher yearly increase in the number of lacunes (β = 0.229, 95% CI 0.130–0.328, p < 0.001), and a higher yearly increase in the number of microbleeds (β = 0.275, 95% CI 0.176–0.375, p < 0.001) compared with individuals without DWI+ lesions (model 1; table 3). These associations remained statistically significant after adjusting for age at the time of the DWI+ lesion (model 2; table 3). The associations between the presence of DWI+ lesions and WMH progression or progression of lacunes were no longer significant after correction for preexisting WMH volume or preexisting lacunes. In contrast, the association between the presence of DWI+ lesions with the yearly increase in the number of microbleeds remained statistically significant after adjusting for the number of preexisting microbleeds (model 3; table 3).
**Table 1** Baseline differences between participants with and without diffusion-weighted imaging–positive (DWI+) lesions

<table>
<thead>
<tr>
<th></th>
<th>DWI−</th>
<th>DWI+</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>No.</strong></td>
<td>464</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td><strong>Demographics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>65.4 ± 8.8</td>
<td>68.8 ± 8.1</td>
<td>0.025</td>
</tr>
<tr>
<td>Male</td>
<td>266 (57)</td>
<td>18 (47)</td>
<td>0.239</td>
</tr>
<tr>
<td>Educational level, y</td>
<td>4.8 ± 1.4</td>
<td>5.0 ± 1.2</td>
<td>0.452</td>
</tr>
<tr>
<td>MMSE</td>
<td>29 (27–29)</td>
<td>28 (27–29)</td>
<td>0.057</td>
</tr>
<tr>
<td><strong>Risk factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td>334 (72)</td>
<td>34 (89)</td>
<td>0.021</td>
</tr>
<tr>
<td>Diabetes</td>
<td>61 (13)</td>
<td>3 (8)</td>
<td>0.454</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>219 (47)</td>
<td>17 (45)</td>
<td>0.867</td>
</tr>
<tr>
<td>Smoking ever</td>
<td>328 (71)</td>
<td>25 (66)</td>
<td>0.580</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>26.7 (24.2–29.8)</td>
<td>26.0 (24.0–30.4)</td>
<td>0.617</td>
</tr>
<tr>
<td><strong>SVD imaging markers</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WMH volume, mL</td>
<td>3.2 (1.2–10.2)</td>
<td>15.2 (6.9–24.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lacunes presence</td>
<td>109 (23)</td>
<td>23 (61)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Microbleed presence</td>
<td>63 (14)</td>
<td>20 (53)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Abbreviations: BMI = body mass index; MMSE = Mini-Mental State Examination; SVD = small vessel disease; WMH = white matter hyperintensities. Data are presented as mean (SD), median (interquartile range), or n (%). Groups represent participants with at least one DWI+ lesion at any MRI time point (DWI+) or no DWI+ lesion (DWI−).

**Table 2** Evolution of diffusion-weighted imaging–positive (DWI+) lesions by location

<table>
<thead>
<tr>
<th>DWI+ lesions</th>
<th>Location</th>
<th>N (pt)</th>
<th>FU available</th>
<th>Evolution into SVD markers</th>
<th>WMH</th>
<th>Cavity</th>
<th>Disappearance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cortex</td>
<td>3 (3)</td>
<td>0</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Supratentorial WM</td>
<td>38 (28)</td>
<td>20 (13)</td>
<td>13 (9)</td>
<td>6 (6)</td>
<td>1 (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Overlapping (cortex and WM)</td>
<td>3 (3)</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Deep GM</td>
<td>4 (4)</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (1)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cerebellum</td>
<td>2 (2)</td>
<td>1 (1)</td>
<td>0</td>
<td>1 (1)</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: FU = follow-up; GM = gray matter; NA = not applicable; WM = white matter; WMH = white matter hyperintensities. Data are presented as N (pt), where N represents the number of DWI+ lesions and pt the number of participants.

**Discussion**

This study shows that DWI+ lesions occur in over 3% of individuals with SVD and evolve into a WMH in around two-thirds and into a cavity in the remaining one-third of individuals. DWI+ lesions are strongly related to the presence and annual progression of SVD markers on MRI.

The prevalence of DWI+ lesions of 3.4% is low when compared to a previous study that found 6 DWI+ lesions in 8% of patients with hypertensive SVD. This discrepancy may be explained by the fact that in this study participants had more severe SVD than in our study. We found that individuals with DWI+ lesions had a greater SVD burden at baseline (WMH volume, lacunes, microbleeds) than those without. Prevalence of DWI+ lesions indeed seems to vary according to disease severity as it ranges from virtually zero in healthy individuals up to 38% in individuals with severe manifestations of SVD such as acute ICH. In our study, we expected DWI+ lesions to be a rare phenomenon, as individuals had predominantly mild to moderate SVD.
Preliminary evidence suggests that acute ischemia, as reflected by DWI+ lesions, plays a role in the origin of SVD markers (WMH, lacunes, microbleeds). This is in line with our findings demonstrating that DWI+ lesions evolve into a WMH or a lacune over a follow-up period of 9 years. We did not find a DWI+ lesion evolving into a microbleed, but this may be because of small numbers. Almost all DWI+ lesions (>95%) converted into markers of SVD on follow-up, whereas in a previous small study approximately half of DWI+ lesions became radiologically inapparent after almost 7 months. However, this study was small and performed in individuals with CAA. It is as yet unclear what causes a DWI+ lesion to disappear, to cavitate, or to evolve into a WMH on follow-up. Recently the severity of the ischemia corresponding to the DWI+ lesion, defined as more pronounced DWI abnormalities (lower lesional apparent diffusion coefficient values) and higher neurofilament light chain protein serum levels (a marker of neuroaxonal damage), were found to be associated with subsequent cavitation.

Although DWI+ lesions seem to play a role in the origin of SVD MRI markers, they may not account for the entire progression of SVD markers on MRI. In fact, the etiology of SVD might be more heterogeneous than previously thought. For instance, almost all DWI+ lesions converted into a focal, isolated WMH rather than that they were expansions of preexisting WMH, suggesting that the progression of preexisting WMH might be due to another pathologic process than that of the development of isolated, focal WMH, such as chronic hypoperfusion. Similarly, recent studies showed a heterogeneous origin of microbleeds, where the majority reflected primary hemorrhages whereas some microbleeds were secondary to a microinfarct. Despite the fact that we could not capture the conversion of a DWI+ lesion into a microbleed in this

---

**Figure 2** Evolution of diffusion-weighted imaging-positive (DWI+) lesions into a spectrum of small vessel disease MRI markers.

DWI+ lesions are shown on diffusion-weighted images, whereas lesion evolution is illustrated on fluid-attenuated inversion recovery images. The insets display T1 (A, B) or T2* images (C). (A) Evolution of a DWI+ lesion into a white matter hyperintensity at 5 and 9 years of follow-up (FU). (B) Evolution of a DWI+ lesion into a lacune at 5 and 9 years of FU. Note that at the time of the DWI+ lesion cavitation is already visible. (C) A DWI+ lesion evolving into a cavity after 5 years of FU with a hemorrhagic component that was already visible at the time of the DWI+ lesion.
study, we did show that DWI+ lesions were associated with annual progression of microbleeds even after adjusting for the previous number of microbleeds. Future studies should further specify the origin of MRI-defined SVD markers.

One of the strengths of this study includes the large cohort of participants with SVD with high external validity for patients with SVD from a general neurology outpatient clinic. Moreover, MRI assessment at 3 different time points allowed us to investigate the MRI signature of DWI+ lesions at multiple moments in time. Furthermore, we used a long-term follow-up period of 9 years to investigate the role of DWI+ lesions in the origin of SVD MRI markers.

Our study also has limitations. Because we were not able to make use of high field strength and high spatial resolution MRI, we may have missed DWI+ lesions <2 mm typically located in cortical regions.30 In addition, we used interscan intervals of several years, which may have resulted in underestimation of the role of DWI+ lesions in the progression of SVD as DWI+ lesions are only visible for several weeks.19,31 Finally, there was a selective loss to follow-up. Participants lost to follow-up were older, had a higher burden of SVD, and had more vascular risk factors compared to individuals who remained in the study, probably leading to an underestimation of DWI+ lesion occurrence and SVD progression. The generalizability of our findings to the general population might be limited as we selected participants with presence of SVD on neuroimaging.

Our study shows that over 3% of individuals with SVD have DWI+ lesions at a random MRI not related to clinical symptoms. Although DWI+ lesions play a role in SVD progression, they probably do not explain all progression of SVD markers on MRI, suggesting that other factors than acute ischemia are at play. Future high-frequency imaging studies with such short MRI intervals that they are able to capture all occurring DWI+ lesions are needed to determine to what extent DWI+ lesions can explain SVD progression, and whether they represent a promising target for future clinical trials or treatments aimed at slowing SVD progression.

**Study funding**

C.J.M.K. was supported by a clinical established investigator grant of the Dutch Heart Foundation (grant 2012 T077) and an Aspasia grant from The Netherlands Organization for Health Research and Development (ZonMw grant 015.008.048). A.M.T. was supported by the Dutch Heart Foundation (grant 2016 T044). F.-E.d.L. was supported by a clinical established investigator grant of the Dutch Heart Foundation (grant 2014 T060) and by a VIDI innovational grant from The Netherlands Organization for Health Research and Development (ZonMw grant 016.126.351).

**Disclosure**

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

**Publication history**

Received by Neurology January 28, 2019. Accepted in final form May 22, 2019.

### Appendix

**Author contributions**

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kim Wiegertjes, MSc</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to data acquisition and analysis, drafted the manuscript and created the figures, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Annemieke ter Telgte, MSc</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

**Table 3** Associations between diffusion-weighted imaging–positive (DWI+) lesions and annual progression of small vessel disease (SVD) in individuals with DWI+ lesions at either the first or second MRI (n = 16)

<table>
<thead>
<tr>
<th>WMH volume progression, mL</th>
<th>Lacunes, incidence, number</th>
<th>Microbleeds, incidence, number</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>95% CI</td>
</tr>
<tr>
<td><strong>Model 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DWI+ lesion</td>
<td>0.173</td>
<td>0.072 to 0.274</td>
</tr>
<tr>
<td><strong>Model 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DWI+ lesion</td>
<td>0.153</td>
<td>0.058 to 0.248</td>
</tr>
<tr>
<td><strong>Model 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DWI+ lesion</td>
<td>−0.006</td>
<td>−0.087 to 0.076</td>
</tr>
</tbody>
</table>

Abbreviations: β = standardized beta; CI = confidence interval; WMH = white matter hyperintensities. Model 1 is univariable; model 2 is adjusted for age; model 3 is adjusted for age and preexisting SVD (WMH volume, number of lacunes or number of microbleeds) at the time of the DWI+ lesion.
Appendix (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pedro B. Oliveira, MSc</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Esther M.C. van Leijsen, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Mayra I. Bergkamp, MSc</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Mohsen Ghafoorian, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Helena M. van der Holst, MD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>David G. Norris, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Bram Plateel, MD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Catharina J.M. Klijn, MD, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Anil M. Tuladhar, MD, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, contributed to data acquisition and analysis, revised the manuscript for intellectual content</td>
</tr>
<tr>
<td>Frank-Erik de Leeuw, MD, PhD</td>
<td>Radboud University Medical Center, Nijmegen, the Netherlands</td>
<td>Author</td>
<td>Contributed to study concept and design, interpreted the data, revised the manuscript for intellectual content, revised the manuscript for intellectual content</td>
</tr>
</tbody>
</table>

References

The role of small diffusion-weighted imaging lesions in cerebral small vessel disease
Kim Wiegertjes, Annemieke ter Telgte, Pedro B. Oliveira, et al.
Neurology 2019;93:e1627-e1634 Published Online before print September 17, 2019
DOI 10.1212/WNL.0000000000008364

This information is current as of September 17, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://n.neurology.org/content/93/17/e1627.full

References
This article cites 28 articles, 12 of which you can access for free at:
http://n.neurology.org/content/93/17/e1627.full#ref-list-1

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
All Cerebrovascular disease/Stroke
http://n.neurology.org/cgi/collection/all_cerebrovascular_disease_stroke
Cohort studies
http://n.neurology.org/cgi/collection/cohort_studies
DWI
http://n.neurology.org/cgi/collection/dwi
Infarction
http://n.neurology.org/cgi/collection/infarction
MRI
http://n.neurology.org/cgi/collection/mri

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.neurology.org/about/about_the_journal#permissions

Reprints
Information about ordering reprints can be found online:
http://n.neurology.org/subscribers/advertise